Skip to content

Cord Blood Alarin Levels in Term Babies

Comparison of Cord Blood Alarin Levels in Term Babies According to Birth Weight

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06333548
Enrollment
87
Registered
2024-03-27
Start date
2023-09-18
Completion date
2024-01-15
Last updated
2024-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birth Weight

Keywords

NEWBORN, ALARİN, UMBİLİCAL CORD BLOOD

Brief summary

In this study, alarin levels in the cord blood of babies with large birth weights will be compared with babies of normal weight. Thus, the investigators aimed to find out whether there is a relationship between babies' birth weights and alarin.

Detailed description

Studies have shown that the galanin neuropeptide family plays a role in regulating appetite, insulin resistance, obesity, hypertension and metabolism. Alarin is a peptide consisting of 25 amino acids. Current research shows that allerin plays an important role in the emergence and development of diabetes and obesity. There are studies that found that the serum alarin level increased significantly in patients with impaired glucose tolerance and type 2 diabetes mellitus. Additionally, studies have found that both non-obese and obese type 2 diabetes mellitus serum alarin levels increase. Studies in the literature are related to adults, and there are no studies on alarin levels in newborn babies. Based on the alarin studies available in the literature, the investigators determined whether there is a relationship between the alarin level and the baby's birth weight by comparing the alarin level in the cord blood of babies with a high birth weight according to their gestational age (both babies of diabetic mothers and babies of non-diabetic mothers) compared to babies whose birth weight is within the normal range. the investigators aimed to find it.

Interventions

DIAGNOSTIC_TESTAppropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM

No intervention

Sponsors

Konya City Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Minutes to 5 Minutes
Healthy volunteers
No

Inclusion criteria

* Babies given consent by their families * Healthy babies

Exclusion criteria

* Babies with syndromic appearance or any accompanying disease * Babies whose family does not give consent

Design outcomes

Primary

MeasureTime frameDescription
Comparison of cord blood alarin levels of babies in different groups according to birth weight (low-appropriate-large) and babies of mothers diagnosed with gestational diabetes regardless of birth weight.postnatal 5 minutesumbilical cord blood alarin levels

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026